(Q53299875)

13 May 2018

title

Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. (English)

1 reference

13 May 2018

author name string

Jing Dong

1

1 reference

13 May 2018

Juncheng Dai

2

1 reference

13 May 2018

Yongqian Shu

3

1 reference

13 May 2018

Shiyang Pan

4

1 reference

13 May 2018

Lin Xu

5

1 reference

13 May 2018

Wenping Chen

6

1 reference

13 May 2018

Yi Wang

7

1 reference

13 May 2018

Guangfu Jin

8

1 reference

13 May 2018

Hongxia Ma

9

1 reference

13 May 2018

Mingfeng Zhang

10

1 reference

13 May 2018

Zhibin Hu

11

1 reference

13 May 2018

Hongbing Shen

12

1 reference

13 May 2018

language of work or name

English

0 references

publication date

16 April 2010

1 reference

13 May 2018

published in

Carcinogenesis

1 reference

13 May 2018

volume

31

1 reference

13 May 2018

issue

6

1 reference

13 May 2018

page(s)

1080-1086

1 reference

13 May 2018

Global cancer statistics, 2002

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

A five-gene signature and clinical outcome in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Gefitinib--a novel targeted approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Epidermal growth factor receptor in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

EGFR overexpression and radiation response in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Epidermal growth factor receptor: a promising target in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Clinical applications of angiogenic growth factors and their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

VEGF polymorphisms and survival in early-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGQ079

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGQ079

1 reference

13 May 2018

1 reference

13 May 2018